West China Hospital COVID-19 vaccine

West China Hospital COVID-19 vaccine

Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of administration	Intramuscular
Identifiers
DrugBank	DB16443

West China Hospital COVID-19 vaccine is a COVID-19 vaccine candidate developed by West China Hospital. ^[1]

Clinical trials

In August 2020, WestVac Biopharma started phase I clinical trials with 168 participants in China. ^[2]

In November, WestVac Biopharma started phase II clinical trials with 960 participants in China ^[3] In February 2021, WestVac Biopharma started phase IIb clinical trials with 4,000 participants in China. Later, WestVac Biopharma is no longer on phase IIb clinical trial. ^[4]

In June 2021, WestVac Biopharma started phase III trials with 40,000 participants including Indonesia, Kenya, and the Philippines. ^[5]

Children and adolescents trials

In August 2021 WestVac Biopharma started phase I/II trials with 600 participants for children and adolescents aged 6-17. ^[6]

References

1. "华西医院研发的重组新冠蛋白疫苗今日起在成都接种". www.wenjiang.gov.cn. Retrieved 13 September 2024.
2. "Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)". clinicaltrials.gov. United States National Library of Medicine. 8 February 2021. Retrieved 20 March 2021.
3. "A Phase II Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
4. "Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
5. "A Global Phase III Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 15 May 2021.
6. "Phase I/II Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 August 2021.